Riconpharma India Profile
Key Indicators
- Authorised Capital ₹ 6.50 Cr
as on 23-10-2024
- Paid Up Capital ₹ 4.83 Cr
as on 23-10-2024
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -19.80%
(FY 2023)
- Profit -9.71%
(FY 2023)
- Ebitda -3.85%
(FY 2023)
- Net Worth 7.49%
(FY 2023)
- Total Assets 9.21%
(FY 2023)
About Riconpharma India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.50 Cr and a paid-up capital of Rs 4.83 Cr, as per Ministry of Corporate Affairs (MCA) records.
Valiveti Brahmaji, Mukteeshwar Gande, and Nageswara Venkata serve as directors at the Company.
- CIN/LLPIN
U24232TG2009PTC062946
- Company No.
062946
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Mar 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Riconpharma India Private Limited offer?
Riconpharma India Private Limited offers a wide range of products and services, including Cardiovascular Drugs & Medication, Cardiac Drugs, Common Disease Medicines, Pharmaceutical Tablets, Anaemia Medicine, TB, Tumor & Cancer Drugs, Anti Cancer Injection, Skin Ointment.
Who are the key members and board of directors at Riconpharma India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Valiveti Brahmaji  | Director | 01-Oct-2014 | Current |
| Mukteeshwar Gande | Director | 12-Feb-2015 | Current |
| Nageswara Venkata | Director | 23-Jan-2018 | Current |
Financial Performance of Riconpharma India.
Riconpharma India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.8% decrease. The company also saw a slight decrease in profitability, with a 9.71% decrease in profit. The company's net worth moved up by a moderate rise of 7.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Riconpharma India?
In 2023, Riconpharma India had a promoter holding of 99.71% and a public holding of 0.29%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indian Institute Of Cancer And Research Private LimitedActive 17 years 7 monthsValiveti Brahmaji is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Riconpharma India?
Riconpharma India has a workforce of 87 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Riconpharma India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Riconpharma India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
